U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07433283) titled 'Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor' on Dec. 19, 2024.
Brief Summary: Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway. CNSI-Fe intratumoral injection has the following three effects: 1. Nanocarbon can increase the content of hydrogen peroxide in tumor cells and tumor microenvironment, and is a reactive oxygen species that catalyzes hydrogen peroxide through the Fenton reaction of iron ions to produce "ferroptosis", whic...